Abtherx扩大了与Gileed Science的合作,以推动治疗性抗体发展。 AbTherx expands collaboration with Gilead Sciences to advance therapeutic antibody development.

Abtherx扩大了与Gileed Science的合作,以加强抗体发现技术,并针对Gileed选定的地区开发治疗性抗体。 AbTherx has expanded its collaboration with Gilead Sciences to enhance antibody discovery technologies and develop therapeutic antibodies targeting Gilead-selected areas. 扩大的伙伴关系最初于2023年6月商定,包括增加转基因鼠技术和扩大研究工作。 Initially agreed upon in June 2023, the expanded partnership includes additional transgenic mouse technologies and extended research efforts. 这一合作旨在推动治疗性抗体发展的创新解决办法,使Gilead和更广泛的生物制药行业都受益。 This collaboration aims to advance innovative solutions for therapeutic antibody development, benefiting both Gilead and the broader biopharma industry.